Emerging treatments for Alzheimer’s disease for non-amyloid and non-tau targets

Ayesha Khan, Anne Corbett, Clive Ballard

Research output: Contribution to journalReview article

Abstract

Introduction: The number of people with dementia, including Alzheimer’s disease, is growing as a result of an ageing global population. Treatments available for AD only alleviate the symptoms of the disease, and are effective in some people with AD for a limited time. There is no disease-modifying treatment available, and despite research efforts, the underlying mechanisms of AD and optimal treatment targets have not been fully elucidated. Amyloid and tau are key pathological markers of AD with ongoing trials targeting both. However, there are also many trials at various stages of development that primarily target other markers and processes implicated in the disease, which are now being investigated. Areas covered: This review summarizes current treatment approaches for AD and explores both repositioned and novel therapies that target non amyloid and non tau mechanisms that are in the clinical trials pipeline. This includes treatments for cognitive and neuropsychiatric symptoms and potentially disease modifying therapies. The studies included in this review have been obtained from searches of PubMed and clinical trials databases. Expert commentary: There is a renewed energy in identifying better treatments for behavioural symptoms of AD using both novel drugs and repositioning existing drugs. Lack of success in clinical trials of drugs targeting amyloid and tau have led to a surge in targeting alternative mechanisms. Progress in the development of biomarkers will provide further tools for clinical trials of potential therapeutics for both symptomatic treatment and disease modification in AD.

Original languageEnglish (US)
Pages (from-to)683-695
Number of pages13
JournalExpert review of neurotherapeutics
Volume17
Issue number7
DOIs
StatePublished - Jul 3 2017

Fingerprint

Alzheimer Disease
Amyloid
Clinical Trials
Therapeutics
Drug Repositioning
Behavioral Symptoms
Neurobehavioral Manifestations
Drug Delivery Systems
PubMed
Dementia
Biomarkers
Databases
Research
Pharmaceutical Preparations
Population

Keywords

  • Alzheimer’s disease
  • anti-inflammatory
  • drug repositioning
  • neuropsychiatric

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Emerging treatments for Alzheimer’s disease for non-amyloid and non-tau targets. / Khan, Ayesha; Corbett, Anne; Ballard, Clive.

In: Expert review of neurotherapeutics, Vol. 17, No. 7, 03.07.2017, p. 683-695.

Research output: Contribution to journalReview article

@article{8e12ece2cdac443c9c31065d0e6ba52b,
title = "Emerging treatments for Alzheimer’s disease for non-amyloid and non-tau targets",
abstract = "Introduction: The number of people with dementia, including Alzheimer’s disease, is growing as a result of an ageing global population. Treatments available for AD only alleviate the symptoms of the disease, and are effective in some people with AD for a limited time. There is no disease-modifying treatment available, and despite research efforts, the underlying mechanisms of AD and optimal treatment targets have not been fully elucidated. Amyloid and tau are key pathological markers of AD with ongoing trials targeting both. However, there are also many trials at various stages of development that primarily target other markers and processes implicated in the disease, which are now being investigated. Areas covered: This review summarizes current treatment approaches for AD and explores both repositioned and novel therapies that target non amyloid and non tau mechanisms that are in the clinical trials pipeline. This includes treatments for cognitive and neuropsychiatric symptoms and potentially disease modifying therapies. The studies included in this review have been obtained from searches of PubMed and clinical trials databases. Expert commentary: There is a renewed energy in identifying better treatments for behavioural symptoms of AD using both novel drugs and repositioning existing drugs. Lack of success in clinical trials of drugs targeting amyloid and tau have led to a surge in targeting alternative mechanisms. Progress in the development of biomarkers will provide further tools for clinical trials of potential therapeutics for both symptomatic treatment and disease modification in AD.",
keywords = "Alzheimer’s disease, anti-inflammatory, drug repositioning, neuropsychiatric",
author = "Ayesha Khan and Anne Corbett and Clive Ballard",
year = "2017",
month = "7",
day = "3",
doi = "10.1080/14737175.2017.1326818",
language = "English (US)",
volume = "17",
pages = "683--695",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "7",

}

TY - JOUR

T1 - Emerging treatments for Alzheimer’s disease for non-amyloid and non-tau targets

AU - Khan, Ayesha

AU - Corbett, Anne

AU - Ballard, Clive

PY - 2017/7/3

Y1 - 2017/7/3

N2 - Introduction: The number of people with dementia, including Alzheimer’s disease, is growing as a result of an ageing global population. Treatments available for AD only alleviate the symptoms of the disease, and are effective in some people with AD for a limited time. There is no disease-modifying treatment available, and despite research efforts, the underlying mechanisms of AD and optimal treatment targets have not been fully elucidated. Amyloid and tau are key pathological markers of AD with ongoing trials targeting both. However, there are also many trials at various stages of development that primarily target other markers and processes implicated in the disease, which are now being investigated. Areas covered: This review summarizes current treatment approaches for AD and explores both repositioned and novel therapies that target non amyloid and non tau mechanisms that are in the clinical trials pipeline. This includes treatments for cognitive and neuropsychiatric symptoms and potentially disease modifying therapies. The studies included in this review have been obtained from searches of PubMed and clinical trials databases. Expert commentary: There is a renewed energy in identifying better treatments for behavioural symptoms of AD using both novel drugs and repositioning existing drugs. Lack of success in clinical trials of drugs targeting amyloid and tau have led to a surge in targeting alternative mechanisms. Progress in the development of biomarkers will provide further tools for clinical trials of potential therapeutics for both symptomatic treatment and disease modification in AD.

AB - Introduction: The number of people with dementia, including Alzheimer’s disease, is growing as a result of an ageing global population. Treatments available for AD only alleviate the symptoms of the disease, and are effective in some people with AD for a limited time. There is no disease-modifying treatment available, and despite research efforts, the underlying mechanisms of AD and optimal treatment targets have not been fully elucidated. Amyloid and tau are key pathological markers of AD with ongoing trials targeting both. However, there are also many trials at various stages of development that primarily target other markers and processes implicated in the disease, which are now being investigated. Areas covered: This review summarizes current treatment approaches for AD and explores both repositioned and novel therapies that target non amyloid and non tau mechanisms that are in the clinical trials pipeline. This includes treatments for cognitive and neuropsychiatric symptoms and potentially disease modifying therapies. The studies included in this review have been obtained from searches of PubMed and clinical trials databases. Expert commentary: There is a renewed energy in identifying better treatments for behavioural symptoms of AD using both novel drugs and repositioning existing drugs. Lack of success in clinical trials of drugs targeting amyloid and tau have led to a surge in targeting alternative mechanisms. Progress in the development of biomarkers will provide further tools for clinical trials of potential therapeutics for both symptomatic treatment and disease modification in AD.

KW - Alzheimer’s disease

KW - anti-inflammatory

KW - drug repositioning

KW - neuropsychiatric

UR - http://www.scopus.com/inward/record.url?scp=85020818887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020818887&partnerID=8YFLogxK

U2 - 10.1080/14737175.2017.1326818

DO - 10.1080/14737175.2017.1326818

M3 - Review article

C2 - 28490260

AN - SCOPUS:85020818887

VL - 17

SP - 683

EP - 695

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 7

ER -